178 results on '"Olszynski, Wojciech P."'
Search Results
2. Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
3. Comparison of Speed of Sound Measures Assessed by Multisite Quantitative Ultrasound to Bone Mineral Density Measures Assessed by Dual-Energy X-Ray Absorptiometry in a Large Canadian Cohort: the Canadian Multicentre Osteoporosis Study (CaMos)
4. Comparison of Short-Term In Vivo Precision of Bone Density and Microarchitecture at the Distal Radius and Tibia Between Postmenopausal Women and Young Adults
5. Normative Data for Multisite Quantitative Ultrasound: The Canadian Multicenter Osteoporosis Study
6. Choice of Lumbar Spine Bone Density Reference Database for Fracture Prediction in Men and Women: A Population-Based Analysis
7. Dual-Energy X-ray Absorptiometry Scan Autoanalysis vs Manual Analysis
8. Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos)
9. Spine-Hip T-Score Difference Predicts Major Osteoporotic Fracture Risk Independent of FRAX ®: A Population-Based Report From CAMOS
10. A critical review of brand and generic alendronate for the treatment of osteoporosis
11. Normative Bone Mineral Density Z-Scores for Canadians Aged 16 to 24 Years: The Canadian Multicenter Osteoporosis Study
12. Safety profile of abatacept in rheumatoid arthritis: A review
13. A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
14. Subsequent entry biologics/biosimilars: a viewpoint from Canada
15. Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions
16. Health-related Quality of Life in Canadian Adolescents and Young Adults: Normative Data Using the SF-36
17. Determinants of health-related quality of life in women with vertebral fractures
18. Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos)
19. Stability of Normative Data for the SF-36: Results of a Three-year Prospective Study in Middle-aged Canadians
20. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database
21. Is There Regional Variation in the SF-36 Scores of Canadian Adults?
22. Are Oral Bisphosphonates Effective in Improving Lumbar Bone Mineral Density in Breast Cancer Survivors With Osteopenia or Osteoporosis?
23. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study
24. Screening men for osteoporosis
25. Management of osteoporosis in men: an update and case example
26. Osteoporosis in men: the quieter half of a silent disease
27. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
28. Osteoporosis in men: Epidemiology, diagnosis, prevention, and treatment
29. Standards and Guidelines for Performing Central Dual-Energy X-Ray Absorptiometry in Premenopausal Women, Men, and Children: A Report From the Canadian Panel† of the International Society of Clinical Densitometry
30. What Predicts Early Fracture or Bone Loss on Bisphosphonate Therapy?
31. The 2002 Canadian bone densitometry recommendations: take-home messages
32. North American Male Reference Population for Speed of Sound in Bone at Multiple Skeletal Sites
33. Positive Effect of Etidronate Therapy Is Maintained After Drug Is Terminated in Patients Using Corticosteroids
34. Evaluation of easily measured risk factors in the prediction of osteoporotic fractures
35. The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women
36. Measurement of muscle and fat in postmenopausal women: precision of previously reported pQCT imaging methods
37. Objectively measured sedentary and physically active time in relation to pQCT-derived muscle adiposity in older adults: cross-sectional results from the Saskatoon Canadian Multi-Centre Osteoporosis Study (CaMos) Cohort
38. Fracture risk prediction: importance of age, BMD and spine fracture status
39. Differences inIn VitroDisintegration Time among Canadian Brand and Generic Bisphosphonates
40. Screening men for osteoporosis
41. A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
42. Spine-Hip T-Score Difference Predicts Major Osteoporotic Fracture Risk Independent of FRAX®: A Population-Based Report From CAMOS
43. Determining whether women with osteopenic bone mineral density have low, moderate, or high clinical fracture risk
44. Using the same bone density reference database for men and women provides a simpler estimation of fracture risk
45. Assessing Fracture Risk and Effects of Osteoporosis Drugs: Bone Mineral Density and Beyond
46. Repeat Low‐Trauma Fractures Occur Frequently Among Men and Women Who Have Osteopenic BMD
47. Bone Strength: The Whole Is Greater Than the Sum of Its Parts
48. The Effects of Antifracture Therapies on the Components of Bone Strength: Assessment of Fracture Risk Today and in the Future
49. Standards for Performing DXA in Individuals With Secondary Causes of Osteoporosis
50. Determinants of health-related quality of life in women with vertebral fractures
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.